The Most Surprising Cro Industry Statistics in 2024

Table of Contents

In today’s fast-paced digital market, Conversion Rate Optimization (CRO) finds itself at the forefront as an indispensable tool in transforming website visitors into loyal customers. As it evolves, industry statistics have become the guiding compass for marketers aiming to enhance their strategies and boost conversion rates. This blog post delves deep into the riveting world of CRO industry statistics. We’ll take you through the latest trends, significant figures, and observational data, lending you a comprehensive understanding of its importance and how it continually shapes the digital marketing landscape. So whether you’re a seasoned marketer or a novice in the field, these statistics are sure to provide valuable insights to arm you with a competitive edge. So let’s embark on this enlightening journey through the numbers behind the scenes of the thriving CRO industry.

The Latest Cro Industry Statistics Unveiled

The Clinical Research Organization (CRO) industry was valued at USD 39 billion in 2019.

Unveiling the substantial valuation of the Clinical Research Organization (CRO) industry at USD 39 billion in 2019 does more than just spew a large number. It paints a vibrant picture of a thriving industry, pulsating with financial health and potential opportunities. Such a statistic dishes out a remarkable snippet of concrete information, highlighting the industry’s economic footprint while simultaneously setting the stage for intricate discussions on trends, growth drivers, and future prospects in the industry. This impressive valuation unarguably offers readers a captivating entry point into a deeper understanding of the grandeur of the CRO industry. The statistic is a testament to the palpable vitality of the industry, and serves as a trustworthy compass for stakeholders eying opportunities in the CRO landscapes.

The CRO market is expected to reach USD 73.77 billion by 2026, growing at a CAGR of 6.6%.

Highlighting the projected growth of the CRO market to a staggering USD 73.77 billion by 2026, with a Compound Annual Growth Rate (CAGR) of 6.6%, provides a crystal-clear snapshot of the burgeoning potential within the Clinical Research Organization (CRO) industry. This crescendo of figures signifies not just a mere upward trend, but a ballooning revolution in the industry. Amidst the wealth of stats and figures available, this one stands like a beacon illuminating the vast realm of opportunities for stakeholders, investors, and players within the CRO landscape. The tantalizing promise of this prospective market size underscores the importance of keeping an eye on the horizon of expanding possibilities in the industry.

The pharmaceutical industry accounts for around 72% of the total CRO market revenue.

In plunging deeper into the realm of CRO Industry statistics, one cannot overlook the giant footprint of the pharmaceutical industry. A monumental 72% of the total CRO market revenue is credited to this industry anchor. Envision each dollar injected into the market as a vote for its value and viability. Thus, with pharmaceutical industry’s overwhelming contribution, it firmly manifests its dominance, influence, and importance within the CRO space. This also underscores the reality that strategies aimed at the CRO industry must prioritise the pharmaceutical sector, considering its fiscal majority. This fact may serve as a lighthouse, guiding future decisions, market analysis, and strategic planning within the CRO industry.

North America dominates the global CRO market, contributing about 43.3% of the total revenue.

Highlighting that North America contributes about 43.3% of the global CRO (Contract Research Organization) market revenue underscores the region’s dominant position in the industry. It paints a picture of North America as the heartbeat driving the global pulse of this industry. Its influence and decision-making power potentially shapes unique trends and advancement in the CRO sector, impacting globally. This vital percentage is more than a number, it’s a testament to the industry’s weight and pull on North American soil, making them a stronghold in the strategic waves the industry rides on worldwide. Therefore, for readers of this blog post, understanding the significant role North America plays can aid in shaping decisions, strategies, and expectations within the global CRO landscape.

About 64% of the total global CRO market revenue is from early-phase development services.

Unveiling the curtain of the CRO industry statistics, an engrossing detail comes to the forefront – nearly 64% of the total global CRO market revenue springs from early-phase development services. This numerical enlightenment holds deep significance. It’s a salient pivot point, demonstrating that the early development services are the economic powerhouse of the CRO market. This implies that the CROs investing their resources and strategies into these domains are the ones reaping significant financial gains. Their success makes clear the vital role of early-phase processes in clinical research, emphasizing the direction budding CROs should consider for vital growth and soaring profits in the global arena. An insight as profound as this is the compass guiding decision-makers in making informed strategic and financial decisions in a competitive global market. Hence, the statistic carves the path for understanding the revenue mix and future trends in the global CRO industry.

Only 50% of businesses are seen outsourcing for medical device trials.

Peering into this revealing number – a mere 50% of businesses outsourcing for medical device trials – paints a vivid picture of the current dynamics within the Contract Research Organization (CRO) industry. This percentage serves as a pivotal liquidity gauge in the CRO landscape, indicating possible underutilization of external expertise in conducting trials for medical devices. It also provides valuable insights into potential growth sections within the sphere. Seen from a different angle, it underscores the even split between businesses that choose to tackle medical device trials in-house, and those who prefer the resource flexibility, expertise, and operational advantages that external organizations offer. Hence, this is a pivotal statistic for stakeholders within the CRO industry, offering a multi-faceted understanding of existing business strategies, challenges, and opportunities.

Approximately 47% of biopharmaceutical companies are expected to increase the level of outsourcing clinical trial-related activities.

Picturing the world of biopharmaceuticals, rapidly evolving and advancing, this forecasted elevation of approximately 47% in outsourcing clinical trial-related activities showcases a potent landscape brimming with opportunities. This prediction, an essential piece of the CRO industry statistics puzzle, underscores the rising faith in Clinical Research Organizations (CROs).

It’s as if we’re peering into a crystal ball, revealing a shifting paradigm towards external expertise for critical research activities. Delving deeper into this insight, it paints a narrative that lifts the curtain on the growing reliance and trust in CROs. Sharing the responsibilities, risks, and rewards, biopharma companies are clearly finding value in collaboration; amplifying their innovation engine and streamlining the route to groundbreaking discoveries.

Every individual engaged in CRO industry will find this influential projection gleaming like a beacon, guiding strategic decisions, initiatives, and investments in this direction. Hence, this statistic is a compass with its needle pointing towards a future where collaborations between biopharma and CRO thrive, strengthening the backbone of medical breakthroughs and healthcare advancements.

During 2019, the top three Clinical Research Organizations, IQVIA, LabCorp (Covance) and Syneos Health, collectively hold 21.5% of the market share.

The diversification and mightiness of the Clinical Research Organization (CRO) marketplace unfolds through the statistic: ‘In 2019, IQVIA, LabCorp (Covance) and Syneos Health, the top three contenders, harnessed 21.5% of the market share’. This highlights the concentration of power within a few key players, shaping the dynamics of the CRO environment. Their prominence is stark, setting precedence in research capabilities, service delivery, and innovative interventions. Recognizing this information paints an accurate picture of the landscape in which both new and existing companies must navigate, providing clues to potential trends and competitive strategies in the sector. Equipped with this knowledge, individuals and companies can better anticipate shifts and prepare for a future shaped by these industry titans.

The oncology segment is projected to reach USD 18.2 billion by 2025 in the CRO industry.

In navigating the narrative of the CRO Industry Statistics, one cannot overlook the dramatic surge predicted in the oncology sector. Anticipated to touch the monumental USD 18.2 billion mark by 2025, this facet within the CRO industry is akin to a meteoric phenomenon heading steadfast towards an economic supernova. This projection is nothing short of a beacon, signalling a paradigm shift in industry priorities, potential research focus, and above all, an arena for investors to seriously consider channeling their resources.

Asia Pacific CRO market size was valued over USD 6.3 billion in 2019 and anticipated to grow around 8.5% from 2020 to 2026.

In the grand tapestry of CRO (Contract Research Organization) Industry Statistics, the hefty value of USD 6.3 billion attributed to the Asia Pacific CRO market in 2019 emerges as a gleaming thread. Not only does it highlight the industry’s significant economic contribution, but also points to the region’s influential standing on the global CRO landscape.

Moreover, the projected growth around 8.5% through 2020 to 2026 broadens the perspective, suggesting not just a steady, but a thriving future for the industry in this part of the world. This unfolding narrative of growth serves as a beacon to potential investors and market players, providing them insights about further opportunities and potential challenges.

To sum it up, the literal and figurative richness of the mentioned statistic presents a multidimensional, gripping view of the CRO Industry in the Asia Pacific region, making it vital for interested stakeholders. So isn’t it an artistic way of looking at the numbers, with every data point weaving a fascinating story of economic growth and opportunities in the CRO Industry?

In 2018, the clinical trial activities by CROs in China contributed RMB 19.6 billion (about USD 3 billion).

Highlighting the statistics from 2018 showing that clinical trial activities by Contract Research Organizations (CROs) in China rendered a significant RMB 19.6 billion (roughly USD 3 billion) is a pivotal point in our discussion surrounding CRO Industry Trends. This towering figure emphasises the dynamic and vivacious role of Chinese CROs in the global clinical trial landscape.

By delving into these stats, it’s clear that China’s CRO industry is contributing robustly in terms of monetary value. The figure showcases the increasing importance and reliance on CROs for efficiently conducted clinical trials. This figure also becomes a testament to the mounting influence of China in the global clinical trials market, thus drawing attention to its potential as a burgeoning hub for future research realms.

Furthermore, this substantial economic contribution indicates a thriving market with chances of growth and innovation, projecting China as an attractive destination for future investments in the field. Therefore, this statistic paints an intriguing picture of the evolving market trends, economic implications, and the potential future trajectories of the global CRO industry.

Medical writing continues to grow within the CRO industry at a five-year CAGR of 7.9%.

Highlighting the ongoing surge in medical writing in the CRO industry, as evidenced by a robust five-year CAGR of 7.9%, creates a compelling narrative for the readers. It not only attests to the dynamism within the sector but also hints at the potential opportunities aspiring medical writers could tap into. Furthermore, it underscores the vital role medical writing plays in upholding the CRO industry’s momentum—thus unearthing a key trend within the statistics in our blog post.


The ever-evolving world of CRO industry continues to showcase significant progress and extraordinary potential. Understanding these industry statistics equips us to make better, more informed decisions for enhancing conversion rates. As the digital landscape continues to grow, the influence of data-driven marketing strategies underscores the importance of CRO. By closely scrutinizing the latest numbers, trends, and insights, businesses and marketers can unlock new opportunities to drive conversions, increase engagement, and ultimately, maximize ROI. The success and growth of your business could very well be seen within these CRO industry statistics. So, keep an eye on them and leverage the potential to create a formidable digital presence.


0. –

1. –

2. –

3. –

4. –

5. –

6. –

7. –

8. –

9. –

10. –


What is the CRO Industry?

The Contract Research Organization (CRO) Industry provides support to the pharmaceutical, biotechnology, and medical device industries in the form of research services outsourced on a contract basis. CROs offer services such as biopharmaceutical development, commercialization, pre-clinical research, clinical research, clinical trials management, and pharmacovigilance.

What is the market size of the CRO industry?

The size of the global contract research organization (CRO) market was estimated at $39.1 billion in 2020 and is projected to reach $61.7 billion by 2028 according to a report by Grand View Research.

What is driving growth in the CRO industry?

The demand for CROs is increasing due to a variety of factors, including the growing need for outsourcing of pharmaceutical and biotechnological services. Other factors include the increasing expenditures in R&D, more investment in new drug development processes, and the need to cut down time and costs related to these activities.

Who are the key players in the CRO industry?

Some of the leading companies in the CRO industry include IQVIA, LabCorp, Syneos Health, Parexel, and PRA Health Sciences.

What challenges do CROs face in the industry?

The challenges for CROs include managing and complying with an ever-changing regulatory environment, maintaining quality control, dealing with high costs associated with clinical trials, the need for specialized knowledge and resources, and challenges in data management and integration.

How we write our statistic reports:

We have not conducted any studies ourselves. Our article provides a summary of all the statistics and studies available at the time of writing. We are solely presenting a summary, not expressing our own opinion. We have collected all statistics within our internal database. In some cases, we use Artificial Intelligence for formulating the statistics. The articles are updated regularly.

See our Editorial Process.

Table of Contents